Liquidia (LQDA) Q2 FY26 earnings call

Liquidia Corporation delivered a robust second quarter, driven by strong commercial execution for YUTREPIA, which continues to gain significant market share in the inhaled prostacyclin market. The company is leveraging its growing cash flow to fund an ambitious R&D pipeline, including the L606 program and multiple new clinical studies, while maintaining a confident outlook for future revenue growth and profitability. Management is focused on expanding prescriber relationships and community penetration, despite ongoing legal uncertainties.